Detalle Publicación

Patient-centred outcomes with maintenance olaparib in newly diagnosed patients with advanced ovarian cancer (OC) and a BRCA mutation (BRCAm) in the phase III SOLO1 trial to support the clinical benefit of prolongation of progression-free survival (PFS)

Autores: Friedlander, M. L.; Moore, K.; Colombo, N.; Scambia, G.; Kim, B. G.; Oaknin, A. ; Lisyanskaya, A.; Floquet, A. ; Leary, A. ; Sonke, G. S. ; Gourley, C. ; Banerjee, S. ; Oza, A. ; González Martín, Antonio; Aghajanian, C.; Bradley, W. ; Lowe, E.; Hettle, R. ; Flood, E.; DiSilvestro, P.

Título de la revista: ANNALS OF ONCOLOGY

ISSN: 0923-7534

Volumen: 30

Número: Suppl.5

Páginas: V405-V406

Fecha de publicación: 2019

DOI: https://doi.org/https://doi.org/10.1093/annonc/mdz250.004

Impacto:

Google Scholar

Menú de navegación

Detalle Publicación

Patient-centred outcomes with maintenance olaparib in newly diagnosed patients with advanced ovarian cancer (OC) and a BRCA mutation (BRCAm) in the phase III SOLO1 trial to support the clinical benefit of prolongation of progression-free survival (PFS)